Join
Live feed
·
PRReleasevia Quantisnow
Galmed Pharmaceuticals Ltd. logo

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GLMD (Galmed Pharmaceuticals Ltd.) and more on Quantisnow.